Tuesday, December 11, 2018 @ 10 am Pacific, 11 am Mountain, Noon Central, 1 pm Eastern
Call In by Phone to Listen Live: (347) 637-2631 or Listen Live Via Computer.
Why do multiple myeloma patients relapse after myeloma therapy? Many myeloma experts believe that myeloma stem cells (or early progenitor cells before they become plasma cells) may not be killed with current myeloma therapies and could be the cause of relapse. Dr. Zhan has identified the presence of CD24 as a strong candidate as a cancer stem cell marker and believes that high CD24 levels lead to more aggressive myeloma and earlier death. His work will test patient samples for the presence of CD24 and assess outcomes while also identifying CD24 monoclonal antibodies that could impact this target.
Dr. Zhan is a recipient of a Myeloma Crowd Research Initiative (MCRI) Award. The Myeloma Crowd created the MCRI because we “Can’t Wait for a Cure.” Through the MCRI we want to help Optimize Myeloma Treatment: Bringing the Right Treatment to the Right Patient at the Right Time. The MCRI is funding three research projects – each with a different focus – that will also integrate with HealthTree, a new tool for myeloma patients. Learn more about HealthTree here:Donate to the MCRI here: http://give.crowdcare.org/mcri.
Thanks to our episode sponsor, Celgene Corporation